Heart Failure with Reduced Ejection Fraction
A condition where the heart muscle is weak and dilated, failing to pump enough blood to the body, characterized by an ejection fraction of 40% or lower.
Emergency Management: Acute Decompensated Heart Failure (Flash Pulmonary Edema) requiring IV loop diuretics, IV vasodilators (nitroglycerin), and non-invasive positive pressure ventilation (BiPAP).
Heart Failure with Reduced Ejection Fraction (HFrEF) is a clinical syndrome characterized by a left ventricular ejection fraction (LVEF) of 40% or less. It occurs when the myocardium is weakened or damaged, impairing the left ventricle's ability to contract effectively and eject a sufficient stroke volume to meet the body's metabolic demands. This systolic dysfunction triggers a cascade of neurohormonal compensatory mechanisms that ultimately lead to progressive cardiac remodeling and volume overload.
Detailed Overview
HFrEF is the classic form of heart failure, heavily driven by ischemic heart disease or cardiomyopathies. The hallmark is an enlarged, dilated left ventricle with poor contractility. The clinical significance of HFrEF lies in its high morbidity, frequent hospitalizations, and significant mortality rate. The management paradigm has shifted from simply treating symptoms with diuretics to utilizing 'guideline-directed medical therapy' (GDMT) that fundamentally blocks the maladaptive neurohormonal pathways (RAAS and SNS), thereby reversing cardiac remodeling and prolonging survival.
Epidemiology & Demographics
Affects approximately 3 million adults in the US (roughly half of all HF cases). Incidence increases steeply with age. Higher prevalence in men and African Americans. The 5-year mortality rate remains approximately 50% despite medical advances.
Etiological Mechanism
The most common etiology is Coronary Artery Disease (CAD) leading to myocardial infarction and subsequent ischemic cardiomyopathy. Non-ischemic causes include viral myocarditis, cardiotoxins (anthracyclines like doxorubicin, alcohol, cocaine), genetic mutations (titin mutations in dilated cardiomyopathy), and long-standing uncontrolled hypertension.
Primary Causes
Myocardial infarction, viral myocarditis (Coxsackie B, Parvovirus), Doxorubicin toxicity, Chagas disease, idiopathic dilated cardiomyopathy.
An initial insult (e.g., myocardial infarction) reduces cardiac output. This triggers baroreceptors to activate the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS) to maintain blood pressure and organ perfusion. Norepinephrine increases heart rate and contractility, while Angiotensin II causes vasoconstriction and stimulates Aldosterone, leading to sodium and water retention. While acutely beneficial, chronic activation of these pathways is profoundly cardiotoxic. They promote apoptosis, interstitial fibrosis, and myocyte hypertrophy, driving pathological left ventricular remodeling (spherical dilation of the LV) and further worsening ejection fraction.
Diagnostic Criteria & Guidelines
Clinical signs/symptoms of heart failure PLUS an echocardiogram demonstrating a Left Ventricular Ejection Fraction (LVEF) ≤ 40%. Elevated natriuretic peptides support the diagnosis.
Foundational Quadruple Therapy for HFrEF: 1. ARNI (Sacubitril/Valsartan 49/51 mg PO BID). 2. Evidence-based Beta-blocker (Metoprolol Succinate 25-200 mg daily or Carvedilol 3.125-25 mg BID). 3. MRA (Spironolactone 25 mg daily). 4. SGLT2 Inhibitor (Dapagliflozin 10 mg daily or Empagliflozin 10 mg daily). Plus Loop Diuretics (Furosemide 20-40 mg daily) strictly for volume overload/congestion relief.
Second-Line & Adjunctive Therapy
Ivabradine 5 mg BID for patients in sinus rhythm with HR ≥ 70 bpm on max tolerated beta-blocker. Hydralazine/Isosorbide Dinitrate specifically for self-identified African American patients with ongoing NYHA Class III-IV symptoms despite quadruple therapy.
Surgical & Procedural Management
Implantable Cardioverter-Defibrillator (ICD) for primary prevention of sudden cardiac death if LVEF ≤ 35% and life expectancy > 1 year. Cardiac Resynchronization Therapy (CRT-D) if QRS duration ≥ 150 ms with LBBB pattern. Advanced options: Left Ventricular Assist Device (LVAD) or Orthotopic Heart Transplantation.
Patient Counseling & Advice
Emphasize that GDMT medications (Beta-blockers, ARNIs, etc.) are meant to make the heart stronger and prolong life over months/years, not necessarily to make them feel instantly better today. Compliance is paramount. Warn against using NSAIDs which worsen fluid retention.
Follow-Up & Monitoring Schedule
Recheck basic metabolic panel (Creatinine, Potassium) 1-2 weeks after initiating or titrating RAAS inhibitors (ARNI, Spironolactone). Echocardiogram every 3-6 months after optimizing medical therapy to check for EF recovery.
Preventive Strategies
Aggressive treatment of hypertension and hyperlipidemia; prompt reperfusion therapy in acute myocardial infarction to save myocardium.
Highly dependent on GDMT adherence and baseline EF. 5-year survival is roughly 50%. However, optimal quadruple therapy significantly reduces mortality and can result in 'Heart failure with improved EF' (LVEF rising > 40%).